Advertisement
Advertisement
IRD
Opus Genetics, Inc. Common Stock
5.18
USDSponsored
-0.10
-1.89%
Sep 18, 15:59 UTC -4
Closed
After-Market
5.25
+0.07
+1.25%
IRD Earnings Reports
Positive Surprise Ratio
IRD beat 26 of 39 last estimates.
67%
Next Report
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$2.08M
/-$0.15
Implied change from Q2 26 (Revenue/ EPS)
+175.16%
/+87.50%
Implied change from Q3 25 (Revenue/ EPS)
-32.53%
/-40.00%
Opus Genetics, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, IRD reported earnings of -0.08 USD per share (EPS) for Q2 26, beating the estimate of -0.15 USD, resulting in a 49.46% surprise. Revenue reached 755.00 thousand, compared to an expected 2.49 million, with a -69.73% difference. The market reacted with a -1.59% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.15 USD, with revenue projected to reach 2.08 million USD, implying an increase of 87.50% EPS, and increase of 175.16% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Opus Genetics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Opus Genetics, Inc. Common Stock reported EPS of -$0.08, beating estimates by 49.46%, and revenue of $755.00K, -69.73% below expectations.
How did the market react to Opus Genetics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -1.59%, changed from $3.78 before the earnings release to $3.72 the day after.
When is Opus Genetics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Opus Genetics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Opus Genetics, Inc. Common Stock is expected to report EPS of -$0.15 and revenue of $2.08M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.